IgA肾病中肾小球C3/C5转化酶的原位检测提示补体持续激活
该研究在53例C3c阳性的原发性IgA肾病患者肾活检组织中评估补体沉积,并对其中33例用邻位连接技术原位检测经典/凝集素途径(C4b2b)和替代途径(C3bBb)的C3/C5转化酶复合物,发现29/33(87.9%)存在持续补体激活,替代途径激活与E1、S1病变、C5b-9沉积及较差肾脏生存相关。
要点
- C3c阳性IgA肾病患者中87.9%可检出C3/C5转化酶,提示持续补体激活。
- 替代途径转化酶C3bBb与MEST-C的E1、S1病变及C5b-9沉积相关。
- 双阴性患者肾脏生存更好(P=.0387),原位转化酶检测或有助于筛选补体靶向治疗获益者。
核心结论
- C3c阳性的IgA肾病患者中87.9%存在持续补体激活,替代途径激活与E1/S1病变、C5b-9沉积及较差肾脏生存相关。
研究设计与样本
- 研究纳入53例原发性IgA肾病且C3c染色阳性的诊断性肾活检患者。
- 其中33例石蜡包埋肾活检组织用邻位连接技术(Duolink®)原位检测C4b2b和C3bBb转化酶复合物。
- 狼疮肾炎和C3肾小球病(C3G)活检作为阳性对照,转化酶信号用QuPath®软件量化并与MEST-C评分、C5b-9染色和临床结局相关分析。
主要发现
- C3bBb转化酶在20/33例(60.6%)C3c阳性患者中检出,中位阳性面积为肾小球表面的15.5(3.4-24.8)‰。
- C4b2b转化酶在22/33例(66.7%)患者中检出,中位阳性面积为8.3(4.1-11.8)‰。
- 两种转化酶同时存在者13/33例(39.4%),4/33例(12.1%)虽C3c染色阳性但未检出转化酶。
- 双阴性患者肾脏生存更好(P=.0387)。
- C3bBb阳性面积与系膜C5b-9沉积强度显著相关(P=.0011);MEST-C评分E1和S1患者诊断时C3bBb强度更高(P=.0251和P=.0004)。
关键数值与推荐
- C3bBb转化酶中位阳性面积15.5(3.4-24.8)‰肾小球表面,见于20/33例(60.6%)。
- C4b2b转化酶中位阳性面积8.3(4.1-11.8)‰,见于22/33例(66.7%)。
- 双转化酶阳性13/33例(39.4%),双阴性4/33例(12.1%),双阴性者肾脏生存更好(P=.0387)。
- C3bBb阳性面积与系膜C5b-9沉积强度相关(P=.0011);E1和S1患者C3bBb强度更高(P=.0251和P=.0004)。
临床怎么用
- 原位转化酶检测可区分正在进行的补体激活与既往沉积,可能帮助筛选最可能从补体靶向治疗中获益的IgA肾病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: The complement system contributes to the progression of immunoglobulin A nephropathy (IgAN) and offers promising therapeutic targets currently under investigation. Identifying appropriate candidates for these treatments is now critical. Currently, complement activation in IgAN is assessed using immunostaining of kidney tissues, a method that lacks precision in differentiating ongoing and past complement activation. METHODS: Complement deposition was assessed in diagnostic kidney biopsies from 53 patients with primary IgAN and positive C3c staining. Immunohistochemistry was used to assess glomerular deposition of C4d and C5b-9, while immunofluorescence was employed for C3b/iC3b and C1q. In situ detection of C3 and C5 convertase complexes from the classical/lectin (C4b2b) and alternative (C3bBb) complement pathways was performed on paraffin-embedded kidney biopsies from 33 of these patients using a proximity ligation assay (Duolink®). Biopsies from patients with lupus nephritis and C3 glomerulopathy (C3G) served as positive controls. Convertase signals were quantified using QuPath® Software and correlated with MEST-C score, C5b-9 staining and clinical outcomes. RESULTS: C3bBb convertases were identified in 20/33 C3c-positive (60.6%) patients, with a median positive area of 15.5 (3.4-24.8) ‰ of the glomerular surface. C4b2b convertases were detected in 22/33 (66.7%) patients, covering a median positive area of 8.3 (4.1-11.8) ‰. Both convertases were present in 13/33 (39.4%) patients, while 4/33 (12.1%) patients had no convertases despite positive C3c staining. Double-negative patients had better renal survival (P = .0387). C3bBb-staining positive area significantly correlated with mesangial C5b-9 deposition intensity (P = .0011). Patients with MEST-C scores E1 and S1 showed greater C3bBb intensity at diagnosis (P = .0251 and P = .0004, respectively). CONCLUSION: Our study demonstrates ongoing complement activation in 29/33 (87.9%) C3c-positive IgAN patients. Notably, activation of the alternative pathway correlated with E1 and S1 lesions, C5b-9 deposition and poorer renal survival. In situ convertase detection may help identify patients most likely to benefit from complement-targeted therapies.
引用
- Obrecht A, Meuleman MS, Olagne J, et al. In situ assessment of glomerular C3/C5 convertases indicates ongoing complement activation in IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 41032319. doi:10.1093/ndt/gfaf200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。